Netscientific Regulatory News (NSCI)

NetScientific plc

("NetScientific" or the "Group")

NetScientific invests in wearable digital health company, Neumitra

London, UK - 7 May 2015 - NetScientific (AIM: NSCI), the biomedical and healthcare technology group, today announced its investment in Neumitra, a digital health company, developing wearable devices and smart software applications for the real-time management of stress.

Neumitra develops embedded biomodules to accurately and continuously measure how the autonomic nervous system is affected by daily stresses, to establish the relationship between brain health and performance. The company uses mobile software to link contextual data, such as events, locations, and activities, with the physiology of stress, sleep, and exercise. Their internet-based analytics platform is designed to preserve participant anonymity while uncovering health risk factors worldwide.

Research has long linked excessive stress to a host of physical and mental health concerns, from heart disease, asthma, and fertility to anxiety disorders and depression. Neumitra's mission is to quantify brain health with a validated stress score for real-time managing of symptoms, identifying their causes, and aiding users and their doctors in managing follow-on health concerns.

Neumitra's biomodules, already available as the neuma biowatch, measure signals associated with the autonomic nervous system including heart rate, skin conductance, temperature, and physical activity to develop a library of personal and population algorithms. The company is currently licensing its biomodules to watch and jewellery manufacturers for widespread applications.

Neumitra is a portfolio company of Breakout Labs and it represents the Group's fifth investment in a Breakout Labs portfolio company since announcing its partnership with Peter Thiel's revolving philanthropic fund in March 2014.

Michael Boyce-Jacino, PhD, US Executive Director at NetScientific commented: "The wearable device market is seeing rapid growth and has the potential to transform many areas of healthcare by enabling real-time tracking and management of symptoms by providing actionable feedback. Stress is an often-overlooked cause of significant healthcare and productivity costs in society which Neumitra is leading the way to better understand and address. Our investment in Neumitra further broadens our digital health portfolio, a key area of focus for the Group."

Robert Goldberg, Ph.D., CEO of Neumitra added: "Whilst the robust consumer interest in fitness trackers and smart watches is exciting, we believe there isn't a product that goes far enough to address health and performance concerns related to stress. At Neumitra, we aim to aggregate large scale analytics and insights to uncover how and when chronic stress adversely impacts the brain and body.

"Our biomodules are giving us compelling data - with more generated every day - that is helping deepen our understanding of stress and what causes it throughout daily life demands. With a biowatch already on the market, we are now focused on incorporating our biomodules into smart devices, such as next-generation watches and jewellery, for health and wellness. NetScientific's investment will help drive our development of applications for brain health concerns around the world."

- Ends -

About NetScientific

NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people's lives and society through improved diagnosis, prognosis and treatment. For more information, please visit the website at www.NetScientific.net 

About Breakout Labs

Breakout Labs, a program of the Thiel Foundation, is reshaping the way early-stage science and technology companies are funded. Founded in 2011, Breakout Labs has supported 22 companies in areas ranging from food science and biomedicine to clean energy. For many of these companies, Breakout Labs was the first external investor. Breakout Labs provides up to $350,000 for companies to achieve specific milestones that are critical to their development. In addition to funding, Breakout Labs companies benefit directly from a 2-year program of mentorship and networking, with access to the Thiel Foundation's large community of investors, innovators, and entrepreneurs. Successful grantees return a capped royalty stream and a small percentage of equity in their company to Breakout Labs and thereby contribute to the next generation of scientific innovation. For more information, see www.BreakoutLabs.org.

About Neumitra

Neumitra is a digital health company in Boston MA developing embedded biomodules to accurately and continuously measure the autonomic nervous system throughout daily life demands. The company is a portfolio company of Peter Thiel's Breakout Labs. The founding team met in 2009 in the Neurotechnology Ventures class at MIT and united around the potential for helping people in their own lives affected by brain health concerns. https://www.neumitra.com/ 

Contact Details